Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phosphorylated adaptor for RNA export (PHAX) is an RNA-binding nuclear transport protein essential for the export of small nuclear RNAs (such as U snRNA) from the nucleus to the cytoplasm in metazoans. PHAX acts as a bridge between the cap binding complex (CBC)-bound snRNA and the export receptor XPO1 (also known as CRM1), and its phosphorylation state controls assembly and disassembly of the export complex: phosphorylation in the nucleus is required for export complex assembly and export, while dephosphorylation in the cytoplasm leads to complex disassembly and recycling of PHAX. PHAX is also involved in the intranuclear trafficking and biogenesis of small nucleolar RNA (snoRNA), binding both precursor and mature forms in a cap-dependent manner. Mutations in PHAX are associated with developmental brain disorders, but it is not considered a direct therapeutic drug target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phosphorylated adaptor for RNA export (PHAX).